Shenzhen Lifotronic Technology Co Net Assets
Shenzhen Lifotronic Technology Co net assets. Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) has net assets worth CN¥2.14 Billion CNY (≈ $313.58 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.53 Billion ≈ $369.58 Million USD) and total liabilities (CN¥382.72 Million ≈ $56.00 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Shenzhen Lifotronic Technology Co net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.14 Billion |
| % of Total Assets | 84.85% |
| Annual Growth Rate | 21.31% |
| 5-Year Change | 67.63% |
| 10-Year Change | N/A |
| Growth Volatility | 19.48 |
Net Assets of Shenzhen Lifotronic Technology Co (2016–2025)
Net assets of Shenzhen Lifotronic Technology Co from 2016 to 2025. This chart illustrates how Shenzhen Lifotronic Technology Co's net assets have evolved over time, based on quarterly financial data. See Shenzhen Lifotronic Technology Co (688389) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Shenzhen Lifotronic Technology Co (2016–2025)
The table below shows the annual net assets of Shenzhen Lifotronic Technology Co from 2016 to 2025. For live market cap and overall valuation, see 688389 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.11 Billion ≈ $308.57 Million |
+2.90% |
| 2024-12-31 | CN¥2.05 Billion ≈ $299.89 Million |
+14.01% |
| 2023-12-31 | CN¥1.80 Billion ≈ $263.05 Million |
+24.53% |
| 2022-12-31 | CN¥1.44 Billion ≈ $211.23 Million |
+14.75% |
| 2021-12-31 | CN¥1.26 Billion ≈ $184.08 Million |
+10.00% |
| 2020-12-31 | CN¥1.14 Billion ≈ $167.34 Million |
+8.95% |
| 2019-12-31 | CN¥1.05 Billion ≈ $153.60 Million |
+57.04% |
| 2018-12-31 | CN¥668.39 Million ≈ $97.81 Million |
+13.82% |
| 2017-12-31 | CN¥587.25 Million ≈ $85.93 Million |
+58.36% |
| 2016-12-31 | CN¥370.82 Million ≈ $54.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Lifotronic Technology Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1952.5% over the analyzed period, indicating profitable operations and earnings retention.
Shenzhen Lifotronic Technology Co Net Assets Breakdown (December 2025)
Shenzhen Lifotronic Technology Co net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥929.52 Million | 43.93% |
| Other Components | CN¥1.19 Billion | 56.07% |
| Total Equity | CN¥2.12 Billion | 100.00% |
Shenzhen Lifotronic Technology Co Competitors by Market Cap
The table below lists competitors of Shenzhen Lifotronic Technology Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ADITYA VISION LTD
NSE:AVL
|
$731.25 Million |
|
Arrowhead Properties Ltd B
JSE:FTB
|
$731.29 Million |
|
BW Offshore Ltd
OL:BWO
|
$731.30 Million |
|
SGSG Science&technology Co Ltd Zhuhai
SHE:300561
|
$731.71 Million |
|
Anhui Coreach Technology Co Ltd
SHE:002983
|
$730.52 Million |
|
Nanjing Kangni Mechanical & Electrical Co Ltd
SHG:603111
|
$730.36 Million |
|
TPK Holding Co Ltd
TW:3673
|
$730.29 Million |
|
Sapphire Foods India Limited
NSE:SAPPHIRE
|
$730.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Lifotronic Technology Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,050,964,593 to 2,115,784,957, a change of 64,820,364 (3.2%).
- Net income of 186,094,700 contributed positively to equity growth.
- Dividend payments of 120,832,975 reduced retained earnings.
- Other comprehensive income decreased equity by 132,273,059.
- Other factors increased equity by 131,831,698.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥186.09 Million | +8.8% |
| Dividends Paid | CN¥120.83 Million | -5.71% |
| Other Comprehensive Income | CN¥-132.27 Million | -6.25% |
| Other Changes | CN¥131.83 Million | +6.23% |
| Total Change | CN¥- | 3.16% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Lifotronic Technology Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.62x to 2.39x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥7.18 | CN¥11.66 | x |
| 2017-12-31 | CN¥1.67 | CN¥11.66 | x |
| 2018-12-31 | CN¥1.73 | CN¥11.66 | x |
| 2019-12-31 | CN¥2.71 | CN¥11.66 | x |
| 2020-12-31 | CN¥2.70 | CN¥11.66 | x |
| 2021-12-31 | CN¥2.97 | CN¥11.66 | x |
| 2022-12-31 | CN¥3.44 | CN¥11.66 | x |
| 2023-12-31 | CN¥4.21 | CN¥11.66 | x |
| 2024-12-31 | CN¥4.81 | CN¥11.66 | x |
| 2025-12-31 | CN¥4.89 | CN¥11.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Lifotronic Technology Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.80%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.93%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.33x
- Recent ROE (8.80%) is below the historical average (12.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 2.80% | 5.95% | 0.35x | 1.34x | CN¥-26.70 Million |
| 2017 | 9.61% | 22.50% | 0.35x | 1.21x | CN¥-2.30 Million |
| 2018 | 12.14% | 25.09% | 0.40x | 1.21x | CN¥14.30 Million |
| 2019 | 9.58% | 23.79% | 0.36x | 1.12x | CN¥-4.41 Million |
| 2020 | 12.59% | 25.99% | 0.43x | 1.13x | CN¥29.65 Million |
| 2021 | 15.16% | 24.46% | 0.53x | 1.17x | CN¥64.80 Million |
| 2022 | 17.47% | 25.58% | 0.54x | 1.26x | CN¥107.50 Million |
| 2023 | 18.29% | 28.68% | 0.49x | 1.30x | CN¥148.91 Million |
| 2024 | 16.84% | 30.09% | 0.40x | 1.41x | CN¥140.30 Million |
| 2025 | 8.80% | 17.93% | 0.37x | 1.33x | CN¥-25.48 Million |
Industry Comparison
This section compares Shenzhen Lifotronic Technology Co's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,728,515,784
- Average return on equity (ROE) among peers: 10.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Lifotronic Technology Co (688389) | CN¥2.14 Billion | 2.80% | 0.18x | $731.09 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $3.98 Billion | -16.09% | 0.31x | $384.61 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $143.67 Million | 40.91% | 1.23x | $4.24 Billion |
| Double Medical Technology Inc (002901) | $2.59 Billion | 26.01% | 0.31x | $2.56 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $5.66 Billion | -0.29% | 0.06x | $494.04 Million |
| Lepu Medical Tech Beijing (300003) | $8.00 Billion | 21.55% | 0.99x | $3.40 Billion |
| INKON Life Technology Co Ltd (300143) | $727.00 Million | 5.81% | 0.17x | $817.03 Million |
| Edan Instruments Inc (300206) | $1.23 Billion | 2.15% | 0.20x | $1.02 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $393.88 Million | 7.34% | 0.20x | $505.98 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.09 Billion | 11.74% | 0.48x | $473.66 Million |
| Sinocare Inc (300298) | $3.47 Billion | 8.19% | 0.71x | $1.56 Billion |
About Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. researches, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. It offers a comprehensive range of in vitro diagnostic equipment and reagents, including electrochemiluminescence immunoassay analyzers, glycated hemoglobin analyzers, specific protein analyzers, blo… Read more